Plasma insulin response to oral and intravenous glucose administration
semaglutide as compared with placebo in terms of cardiovascular safety in people with type 2 diabetes at increased cardiovascular risk [31]
BMC genomics 16, 687, doi: 10.1186/s12864-015-1828-2 (2015)
There is a concern that pre-colonoscopy bowel cleansing regimens will not be as effective due to altered transit
Citation100,Citation101 This positively impacts various pathophysiological conditions, including type 2 diabetes, obesity, and non-alcoholic fatty liver disease
[1] [2] It does not hold a marketing authorisation from the MHRA or EMA, and is therefore only available through approved clinical trials or, in exceptional circumstances, via a regulated NHS specials supply route